Literature DB >> 17517852

Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir.

Bruno Marchand1, Kirsten L White, John K Ly, Nicolas A Margot, Ruth Wang, Martin McDermott, Michael D Miller, Matthias Götte.   

Abstract

The ATP-dependent phosphorolytic excision of nucleoside analogue reverse transcriptase inhibitors can diminish their inhibitory effects on human immunodeficiency virus replication. Previous studies have shown that excision can occur only when the reverse transcriptase complex exists in its pretranslocational state. Binding of the next complementary nucleotide causes the formation of a stable dead-end complex in the posttranslocational state, which blocks the excision reaction. To provide mechanistic insight into the excision of the acyclic phosphonate nucleotide analog tenofovir, we compared the efficiencies of the reaction in response to changes in the translocation status of the enzyme. We found that rates of excision of tenofovir with wild-type reverse transcriptase can be as high as those seen with 3'-azido-3'-deoxythymidine monophosphate (AZT-MP). Thymidine-associated mutations, which confer >100-fold and 3-fold decreased susceptibility to AZT and tenofovir, respectively, caused substantial increases in the efficiency of excision of both inhibitors. However, in contrast to the case for AZT-MP, the removal of tenofovir was highly sensitive to dead-end complex formation. Site-specific footprinting experiments revealed that complexes with AZT-terminated primers exist predominantly pretranslocation. In contrast, complexes with tenofovir-terminated primers are seen in both configurations. Low concentrations of the next nucleotide are sufficient to trap the complex posttranslocation despite the flexible, acyclic character of the compound. Thus, the relatively high rate of excision of tenofovir is partially neutralized by the facile switch to the posttranslocational state and by dead-end complex formation, which provides a degree of protection from excision in the cellular environment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17517852      PMCID: PMC1932533          DOI: 10.1128/AAC.00314-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  44 in total

1.  Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis.

Authors:  Adrian S Ray; Eisuke Murakami; Aravind Basavapathruni; Joseph A Vaccaro; Dagny Ulrich; Chung K Chu; Raymond F Schinazi; Karen S Anderson
Journal:  Biochemistry       Date:  2003-07-29       Impact factor: 3.162

2.  Site-specific footprinting reveals differences in the translocation status of HIV-1 reverse transcriptase. Implications for polymerase translocation and drug resistance.

Authors:  Bruno Marchand; Matthias Götte
Journal:  J Biol Chem       Date:  2003-06-20       Impact factor: 5.157

3.  Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation.

Authors:  Peter R Meyer; Johan Lennerstrand; Suzanne E Matsuura; Brendan A Larder; Walter A Scott
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 4.  Inhibition of HIV-1 reverse transcription: basic principles of drug action and resistance.

Authors:  Matthias Götte
Journal:  Expert Rev Anti Infect Ther       Date:  2004-10       Impact factor: 5.091

5.  Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.

Authors:  Paul L Boyer; Tomozumi Imamichi; Stefan G Sarafianos; Edward Arnold; Stephen H Hughes
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

Authors:  Michael D Miller; Nicolas Margot; Biao Lu; Lijie Zhong; Shan-Shan Chen; Andrew Cheng; Michael Wulfsohn
Journal:  J Infect Dis       Date:  2004-02-10       Impact factor: 5.226

7.  Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir.

Authors:  Steve Tuske; Stefan G Sarafianos; Arthur D Clark; Jianping Ding; Lisa K Naeger; Kirsten L White; Michael D Miller; Craig S Gibbs; Paul L Boyer; Patrick Clark; Gang Wang; Barbara L Gaffney; Roger A Jones; Donald M Jerina; Stephen H Hughes; Eddy Arnold
Journal:  Nat Struct Mol Biol       Date:  2004-04-25       Impact factor: 15.369

8.  Impact of the translocational equilibrium of HIV-1 reverse transcriptase on the efficiency of mismatch extensions and the excision of mispaired nucleotides.

Authors:  Bruno Marchand; Matthias Götte
Journal:  Int J Biochem Cell Biol       Date:  2004-09       Impact factor: 5.085

9.  ATP-dependent removal of nucleoside reverse transcriptase inhibitors by human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Lisa K Naeger; Nicolas A Margot; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

10.  Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.

Authors:  Kirsten L White; James M Chen; Nicolas A Margot; Terri Wrin; Christos J Petropoulos; Lisa K Naeger; S Swaminathan; Michael D Miller
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

View more
  17 in total

1.  Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tract.

Authors:  Pinar Iyidogan; Karen S Anderson
Journal:  Antiviral Res       Date:  2012-06-01       Impact factor: 5.970

2.  Formation of a quaternary complex of HIV-1 reverse transcriptase with a nucleotide-competing inhibitor and its ATP enhancer.

Authors:  Maryam Ehteshami; Monique Nijhuis; Jean A Bernatchez; Christopher J Ablenas; Suzanne McCormick; Dorien de Jong; Dirk Jochmans; Matthias Götte
Journal:  J Biol Chem       Date:  2013-04-18       Impact factor: 5.157

3.  Mechanisms involved in the selection of HIV-1 reverse transcriptase thumb subdomain polymorphisms associated with nucleoside analogue therapy failure.

Authors:  Gilberto Betancor; Maria C Puertas; María Nevot; César Garriga; Miguel A Martínez; Javier Martinez-Picado; Luis Menéndez-Arias
Journal:  Antimicrob Agents Chemother       Date:  2010-08-23       Impact factor: 5.191

Review 4.  Reverse transcriptase in motion: conformational dynamics of enzyme-substrate interactions.

Authors:  Matthias Götte; Jason W Rausch; Bruno Marchand; Stefan Sarafianos; Stuart F J Le Grice
Journal:  Biochim Biophys Acta       Date:  2009-08-07

Review 5.  Recent findings on the mechanisms involved in tenofovir resistance.

Authors:  Pinar Iyidogan; Karen S Anderson
Journal:  Antivir Chem Chemother       Date:  2014-12-16

6.  Mechanism of inhibition of HIV-1 reverse transcriptase by 4'-Ethynyl-2-fluoro-2'-deoxyadenosine triphosphate, a translocation-defective reverse transcriptase inhibitor.

Authors:  Eleftherios Michailidis; Bruno Marchand; Eiichi N Kodama; Kamlendra Singh; Masao Matsuoka; Karen A Kirby; Emily M Ryan; Ali M Sawani; Eva Nagy; Noriyuki Ashida; Hiroaki Mitsuya; Michael A Parniak; Stefan G Sarafianos
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

7.  Allosteric regulation of HIV-1 reverse transcriptase by ATP for nucleotide selection.

Authors:  Masaru Yokoyama; Hiromi Mori; Hironori Sato
Journal:  PLoS One       Date:  2010-01-25       Impact factor: 3.240

8.  Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.

Authors:  Kamalendra Singh; Bruno Marchand; Karen A Kirby; Eleftherios Michailidis; Stefan G Sarafianos
Journal:  Viruses       Date:  2010-02-11       Impact factor: 5.048

9.  Clicking 3'-azidothymidine into novel potent inhibitors of human immunodeficiency virus.

Authors:  Venkata Ramana Sirivolu; Sanjeev Kumar V Vernekar; Tatiana Ilina; Nataliya S Myshakina; Michael A Parniak; Zhengqiang Wang
Journal:  J Med Chem       Date:  2013-10-28       Impact factor: 7.446

10.  The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study.

Authors:  Joy Y Feng; John K Ly; Florence Myrick; Derrick Goodman; Kirsten L White; Evguenia S Svarovskaia; Katyna Borroto-Esoda; Michael D Miller
Journal:  Retrovirology       Date:  2009-05-13       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.